<div id="readability-page-1"><div><ul> <li>Madrigal Pharmaceuticals recently reported first-quarter 2026 results, posting a net loss of US$94.39 million, or US$3.25 per share, compared with a loss of US$73.24 million, or US$2.61 per share, a year earlier.</li> <li>Alongside these wider losses, the company highlighted strong year-on-year revenue growth from Rezdiffra and reinforced its MASH-focused story ahead of a May 2026 Fierce Biotech Week presentation featuring its Chief Medical Officer.</li> <li>Next, we’ll examine how Rezdiffra’s early commercial traction and physician enthusiasm could reshape Madrigal’s investment narrative for long-term investors.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</p><h2>Madrigal Pharmaceuticals Investment Narrative Recap</h2><p>To own Madrigal, you need to believe Rezdiffra can become a foundational MASH therapy while the company manages rising costs and competitive pressure. The latest results show a wider quarterly net loss, but the core near term catalyst remains Rezdiffra’s commercial uptake and physician adoption signals. The biggest current risk is that high R&amp;D and SG&amp;A spending, combined with reimbursement pressure, keep losses elevated and increase the likelihood of further financing.</p> <p>The most relevant recent update here is the first quarter 2026 earnings release, which showed a net loss of US$94.39 million compared with US$73.24 million a year earlier. This reinforces the tension between early Rezdiffra revenue growth and the cash burn needed to support launch efforts. How payers respond on pricing and access, and whether Rezdiffra’s revenue can outpace rising expenses, will be central to how this catalyst and risk play out.</p> <p>Yet behind Rezdiffra’s early traction, investors should also be aware of rising costs and potential financing needs that could...</p> <p>Read the full narrative on Madrigal Pharmaceuticals (it's free!)</p><p>Madrigal Pharmaceuticals' narrative projects $2.5 billion revenue and $822.9 million earnings by 2028.</p><p>Uncover how Madrigal Pharmaceuticals' forecasts yield a $671.07 fair value, a 28% upside to its current price.</p><h2>Exploring Other Perspectives</h2> <p>Some of the lowest ranked analysts were already cautious, assuming about US$2.8 billion of revenue and US$569.3 million of earnings by 2029, which contrasts sharply with more optimistic views and highlights how much opinions can differ as you weigh this new earnings miss against earlier expectations.</p><p>Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth over 3x more than the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>These stocks are moving-our analysis flagged them today. Act fast before the price catches up:</p><ul><li>AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.</li><li>We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

MDGL

LABU

<p>Madrigal Pharmaceuticals reported a Q1 2026 net loss of $94.39 million, up from $73.24 million a year prior, despite strong revenue growth from Rezdiffra. The company emphasizes the importance of Rezdiffra's commercial uptake and physician adoption for its investment narrative. Rising costs and reimbursement pressures pose risks, while forecasts suggest potential revenue of $2.5 billion by 2028. Analysts' opinions vary significantly, highlighting the uncertainty surrounding Madrigal's financial outlook.</p>

Simplywall

Madrigal Pharma

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

VG Health

Invesco Biotechnology & Genome ETF

iShares US Pharma

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders